association

Full identifier: http://purl.org/np/RAcDY4XIV5WfySQB3OXMKQ5JU2VqxJgaKLe7qwn2ky93o#association

Assigned to 1 class:

Minted in Nanopublication

 RAcDY4XIV5 comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAcDY4XIV5...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "for all patients eplerenone tablets are contraindicated in all patients with serum potassium 5 5 meq l at initiation creatinine clearance 3 ml min or concomitant administration of strong cyp3a4 inhibitors e g ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir and nelfinavir see drug interactions 7 1 cyp3a4 inhibitors clinical pharmacology 12 3 pharmacokinetics for patients treated for hypertension eplerenone tablets is contraindicated for the treatment of hypertension in patients with type 2 diabetes with microalbuminuria serum creatinine 2 mg dl in males or 1 8 mg dl in females creatinine clearance 5 ml min or concomitant administration of potassium supplements or potassium sparing diuretics e g amiloride spironolactone or triamterene see warnings and precautions 5 1 hyperkalemia adverse reactions 6 2 clinical laboratory test findings 7 drug interactions clinical pharmacology 12 3 pharmacokinetics for all patients serum potassium 5 5 meq l at initiation 4 creatinine clearance 3 ml min 4 concomitant use with strong cyp3a4 inhibitors 4 7 1 for the treatment of hypertension type 2 diabetes with microalbuminuria 4 serum creatinine 2 mg dl in males 1 8 mg dl in females 4 creatinine clearance 5 ml min 4 concomitant use of potassium supplements or potassium sparing diuretics 4" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAcDY4XIV5... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-12T15:36:15.751+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAcDY4XIV5... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAcDY4XIV5... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAcDY4XIV5... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:36:15.751Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
for all patients eplerenone tablets are contraindicated in all patients with serum potassium 5 5 meq l at initiation creatinine clearance 3 ml min or concomitant administration of strong cyp3a4 inhibitors e g ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir and nelfinavir see drug interactions 7 1 cyp3a4 inhibitors clinical pharmacology 12 3 pharmacokinetics for patients treated for hypertension eplerenone tablets is contraindicated for the treatment of hypertension in patients with type 2 diabetes with microalbuminuria serum creatinine 2 mg dl in males or 1 8 mg dl in females creatinine clearance 5 ml min or concomitant administration of potassium supplements or potassium sparing diuretics e g amiloride spironolactone or triamterene see warnings and precautions 5 1 hyperkalemia adverse reactions 6 2 clinical laboratory test findings 7 drug interactions clinical pharmacology 12 3 pharmacokinetics for all patients serum potassium 5 5 meq l at initiation 4 creatinine clearance 3 ml min 4 concomitant use with strong cyp3a4 inhibitors 4 7 1 for the treatment of hypertension type 2 diabetes with microalbuminuria 4 serum creatinine 2 mg dl in males 1 8 mg dl in females 4 creatinine clearance 5 ml min 4 concomitant use of potassium supplements or potassium sparing diuretics 4
Leoni Bücken
2021-06-12T13:36:15.751Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:36:15.751Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:36:15.751Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:36:15.751Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:36:15.751Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:36:15.751Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:36:15.751Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)